1. DePuy Synthes launches spinal implants
DePuy Synthes announced in an April 26 press release that it has launched its Proti 360º integrated titanium family of interbody devices that are designed to be used with patients who have degenerative disc disease in their neck and back. The Proti 360º is designed to maximize the potential for bone growth while offering the benefits of PEEK and titanium. Titanium creates a bioactive surface that promotes attachment and bone-forming cell growth.
2. PavMed to commercialize EsoCheck Barrett’s Esopagus biomarker test
PavMed has signed a letter of intent with Case Western Reserve University to commercialize its EsoCheck technology, according to an April 24 press release. EsoCheck is a non-invasive, cell-sampling device that features highly accurate DNA biomarkers that detect Barrett’s Esophagus. The device is offered as an office-based test that takes five minutes to complete. A patient swallows a vitamin pill-sized capsule that has a small inflatable balloon attached to a thin catheter. The balloon swabs the target area for cells as the catheter is removed. Then the sample can be tested for DNA biomarkers.
3. Cerus wins Health Canada nod for Intercept blood system
Cerus announced in an April 25 press release that it has won Health Canada approval to commercialize its Intercept Blood System for platelets. The system is designed for ex vivo treatment and storage of platelet components. It is used to inactivate a broad range of pathogens like viruses, bacteria and protozoan parasites to reduce the risk of transfusion-transmitted infections.
